VAN... NEED HELP. I'M UP 68% on KOPN after I doubled up!!! I must be lucky. or this stock moved I didn't see... KOPN is in the Ideas For Now Portfolio so I don't want to screw up a good winner... could you take a look at the TA?
You are using an out of date browser. It may not display this or other websites correctly.
You should upgrade or use an alternative browser.
You should upgrade or use an alternative browser.
Ideas For Now-
- Thread starter stonedinvestor
- Start date
Anybody see a chart on STNE Co. Jesus. What a thing of beauty. Buffett give the man credit he's involved here and the stk has doubled. or more. They do Paypal like stuff just in Brazil and I guess that's enough... One has to wonder where the stock price goes if they branch out?
STNE should be on our watch list with FOUR... I mean STNE has 50+ % margins.... much better than Shift4 Payments....
STNE should be on our watch list with FOUR... I mean STNE has 50+ % margins.... much better than Shift4 Payments....
Lets Do this-!
CohBar, Inc. (CWBR)
NasdaqCM - NasdaqCM Real Time Price. Currency in USD
1.5250+0.1150 (+8.16%)<----- common baby spark spark... we are so close...
As of 10:05AM EST. Market open.
CohBar, Inc. (CWBR)
NasdaqCM - NasdaqCM Real Time Price. Currency in USD
1.5250+0.1150 (+8.16%)<----- common baby spark spark... we are so close...
As of 10:05AM EST. Market open.
Ok so one thing that I look for in a Biotech is a platform or new way of doing things that may lead to many many drugs. The reason for that is if it works 9 times out of 10 these companies are bought before they can realize their save the world abilities. So i have one Bicycle it's a stock nobody cares about but me but it's a shot in the dark that their way of doing things leads to a whole new breakthrough for many diseases. The larger the target populations the better!
Enter CohBar-- Why do we like this company? From the last Earnings call) ) ) )
Steve Engle
Thanks, Jeff. Welcome, everyone, to our call. We believe CohBar represents a rare opportunity in biotech and that mitochondria-based therapeutics represent a treasure trove of potential therapeutic agents for multiple diseases. We are elucidating the function of the peptides defined by sequences in the human mitochondrial genome. We are reading the language of the mitochondria, speaking to the rest of the body. Based on our progress to date, we expect this will enable us to develop key therapies in multiple chronic and age-related diseases.
Let’s start our review of the quarter with 3 key points. In the Phase Ib study, half of the planned subjects have reached the end of their treatment. We made significant progress with our preclinical projects. For example, we announced new preclinical data showing enhanced effects when our antifibrotic peptide is combined with a commonly prescribed IPF drug. And third, based on continued progress in the antifibrotic program, we plan to nominate a second clinical candidate in the first quarter of 2021 based on completing several research tasks.
Next slide? What is the CohBar opportunity? We believe that we are the leaders in developing a new class of therapeutics based on our founder’s discovery that mitochondrial peptides regulate multiple systems in the body. Think about that. Prior to 2001 Drs. Cohen and Barzilai’s discovery, people thought mitochondria were just the powerhouses of the cell and not a key player in regulating some of the body’s key functions. Because it is a new class of drugs, we believe mitochondria-based therapeutics represent a large, untapped and exciting group of potential therapeutics.
Amazingly, our Chief Science Officer, Ken Cundy and his scientists have discovered over 100 peptides in the mitochondrial genome and developed over 1,000 analogs. It is like we have 100 keys on the wall and we’re taking them down one-by-one to discover which biological clock or lock they open. Based on our research results, we believe that some keys may actually open multiple locks, such as NASH and obesity. We are targeting a wide range of diseases that are associated with mitochondrial dysfunction. And because we’re targeting the problem at the cellular level, we believe mitochondrial peptides will work on the cause rather than just the symptoms. Mitochondria-based therapeutics benefit from over 1 billion years of evolution and may generate entirely new approaches to treating diseases.<---- Yowsa!
Enter CohBar-- Why do we like this company? From the last Earnings call) ) ) )
Steve Engle
Thanks, Jeff. Welcome, everyone, to our call. We believe CohBar represents a rare opportunity in biotech and that mitochondria-based therapeutics represent a treasure trove of potential therapeutic agents for multiple diseases. We are elucidating the function of the peptides defined by sequences in the human mitochondrial genome. We are reading the language of the mitochondria, speaking to the rest of the body. Based on our progress to date, we expect this will enable us to develop key therapies in multiple chronic and age-related diseases.
Let’s start our review of the quarter with 3 key points. In the Phase Ib study, half of the planned subjects have reached the end of their treatment. We made significant progress with our preclinical projects. For example, we announced new preclinical data showing enhanced effects when our antifibrotic peptide is combined with a commonly prescribed IPF drug. And third, based on continued progress in the antifibrotic program, we plan to nominate a second clinical candidate in the first quarter of 2021 based on completing several research tasks.
Next slide? What is the CohBar opportunity? We believe that we are the leaders in developing a new class of therapeutics based on our founder’s discovery that mitochondrial peptides regulate multiple systems in the body. Think about that. Prior to 2001 Drs. Cohen and Barzilai’s discovery, people thought mitochondria were just the powerhouses of the cell and not a key player in regulating some of the body’s key functions. Because it is a new class of drugs, we believe mitochondria-based therapeutics represent a large, untapped and exciting group of potential therapeutics.
Amazingly, our Chief Science Officer, Ken Cundy and his scientists have discovered over 100 peptides in the mitochondrial genome and developed over 1,000 analogs. It is like we have 100 keys on the wall and we’re taking them down one-by-one to discover which biological clock or lock they open. Based on our research results, we believe that some keys may actually open multiple locks, such as NASH and obesity. We are targeting a wide range of diseases that are associated with mitochondrial dysfunction. And because we’re targeting the problem at the cellular level, we believe mitochondrial peptides will work on the cause rather than just the symptoms. Mitochondria-based therapeutics benefit from over 1 billion years of evolution and may generate entirely new approaches to treating diseases.<---- Yowsa!
Another stock teetering on breaking out-!
TA- PT $40+
TA- PT $40+
- For the third quarter, TravelCenters Of America had an EPS of $0.65, compared to year-ago quarter EPS of $0.23. the stock has a 52-week-high of $35.60.
Dow Inc., Olin, Tronox named among 2021 chemical top picks at Alembic Global
Olin a good co I have used in the past.
Olin a good co I have used in the past.
Doing our bit to Help.
XPO Logistics begins U.S. deliveries of COVID-19 vaccine 12/18 XPO, PFE, BNTX XPO Logistics (XPO) has confirmed that its expedited transportation fleet began delivering Pfizer (PFE)-BioNTech (BNTX) COVID-19 vaccine shipments this week in support of Operation Warp Speed, the US government's public-private alliance to combat the pandemic. The company has deployed its fleet of state-of-the-art tractor-trailers to support partners in moving the heat-sensitive vaccine to US distribution points and healthcare facilities. The thermal-mapped equipment is outfitted with sensors that constantly monitor the temperature inside the trailer and alert the driver to any variances. XPO has allocated additional transportation resources to handle COVID-19 vaccines awaiting approval for emergency use.
XPO Logistics begins U.S. deliveries of COVID-19 vaccine 12/18 XPO, PFE, BNTX XPO Logistics (XPO) has confirmed that its expedited transportation fleet began delivering Pfizer (PFE)-BioNTech (BNTX) COVID-19 vaccine shipments this week in support of Operation Warp Speed, the US government's public-private alliance to combat the pandemic. The company has deployed its fleet of state-of-the-art tractor-trailers to support partners in moving the heat-sensitive vaccine to US distribution points and healthcare facilities. The thermal-mapped equipment is outfitted with sensors that constantly monitor the temperature inside the trailer and alert the driver to any variances. XPO has allocated additional transportation resources to handle COVID-19 vaccines awaiting approval for emergency use.
ADDING GO- PRO TO THE IDEAS FOR NOW PORTFOLIO! @$9.00
GPRO
GPRO
VAN Give me some Kopin advice! They do stuff that goes into the glasses Vuzi glasses not sure about them exactly but in general smart glasses... KOPN>>>
Why am I adding GoPro. the simple reason I have two people I know that got Go Pros for Christmas and in each case I thought this was interesting, in each case there was silly vests and other go pro holding equipment or wearables.. so you get more action than just the Go Pro camera!!! I think that is key come earnings time.
X-mas sales were online. Go Pros' are online...
X-mas sales were for active things that get us out of the house. Hiking, sking motorbike ATV... etc... camping all reasons to have a Go Pro on your boat or raft or canoooo.
Go Pro qualifies...
X-mas sales were online. Go Pros' are online...
X-mas sales were for active things that get us out of the house. Hiking, sking motorbike ATV... etc... camping all reasons to have a Go Pro on your boat or raft or canoooo.
Go Pro qualifies...